Clinical trial · Observational
Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms
Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms in Cetuximab Activity Used in Palliative Treatment of Upper Aerodigestive Tract Tumours
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hypothesis: Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally advanced and inoperable upper aerodigestive tract cancers. Actually, no predictive biomarkers of Cetuximab antitumor activity are known in this setting. It has been shown recently that FCγRIIIA and FCγRIIA receptor polymorphisms played a role in antitumor activity of trastuzumab and cetuximab. The investigators therefore hypothesized that FCγRIIIA and FCγRIIA receptor polymorphisms may play a predictive role in Cetuximab effectiveness in upper aerodigestive tract cancers with recurrence or metastatic disease that make them inaccessible to loco regional treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Upper Gingival Squamous Cell Carcinoma | Upper Gingival Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetuximab | Drug | Cetuximab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- UGSCS
- description
- Patients with Upper Gingival Squamous Cell Carcinoma initiating Cetuximab treatment
- interventionNames
- Drug: Cetuximab
Primary outcomes (2)
- measure
- Polymorphism of FCGR2 Gene
- timeFrame
- At treatment initiation
- description
- Polymorphism of FCGR2A gene is expressed according to 3 modalities : RR / RH / HH Genomic DNA will be extracted from whole blood tubes and redissolved in 100 µl 1× TE buffer and purified on GFX columns (Amersham-Biosciences). The quantity and quality of the DNA will be checked by agarose gel electrophoresis in the presence of ethidium bromide. Polymorphisms will be detected by PCR followed by pyrosequencing.
- measure
- Polymorphism of FCGR3A Gene
- timeFrame
- At treatment initiation
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with recurrent or metastatic squamous cell carcinomas of the upper aero-digestive tract * Patient with loco-regional extension not readily treatable * 18 years * Follow up in participant center * Patient information and consent for study participation * Patient presented in multidisciplinary meeting (RCP) in Aquitaine and for whom a treatment containing cetuximab has been proposed * Belong to a social security system Exclusion Criteria: * Pregnancy * Patient with psychological, social, family or geographical reason, who could not be treated or monitored regularly by study criteria, * Patients deprived of liberty or under guardianship or who could not give consent for study participation * Inclusion in another study
References
Publications (0)
Data not yet available